Reference: Classen, B. (2021). US COVID-19 vaccines proven to cause more harm than good based on pivotal clinical trial data analysed using the proper scientific endpoint, “all cause severe morbidity”. Trends in Internal Medicine, 1(1), 1-6. Summary: The article by J. Bart Classen critiques the three COVID-19 vaccines approved in the US, asserting that they […]
Reference: Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Cohen, D., Muhsen, K., Chodick, G., & Patalon, T. (2021). Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv. https://doi.org/10.1101/2021.08.24.21262415 Summary: This study compares the long-term protection provided by natural immunity from previous SARS-CoV-2 infection to that from the
Reference: Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Magen, E., & Vinker, S. (2021). Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv. https://doi.org/10.1101/2021.08.03.21261496 Summary: This study investigates the decay of SARS-CoV-2 IgG antibodies in individuals vaccinated with two doses of
Reference: South African Health Products Regulatory Authority. (2021, August 20). SAHPRA statement on adverse events following immunisation (AEFIs) with COVID-19 vaccines. Summary: The South African Health Products Regulatory Authority (SAHPRA) oversees the safety of COVID-19 vaccines in collaboration with the National Department of Health (NDoH). Since the national vaccination roll-out commenced on 17 May 2021,
Reference: Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Morbidity and Mortality Weekly Report, 70(32), 1081-1083. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7032e1-H.pdf Summary: A study conducted in Kentucky during May-June 2021 assessed the impact of COVID-19 vaccination on reinfection rates among individuals previously
Reference: Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination – Kentucky, May–June 2021. Morbidity and Mortality Weekly Report, 70(32), 1081-1083. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7032e1-H.pdf Summary: A study conducted in Kentucky investigated the impact of COVID-19 vaccination on reinfection rates among individuals previously infected
Reference: Riemersma, K. K., Haddock, L. A. III, Wilson, N. A., Minor, N., Eickhoff, J., Grogan, B. E., Kita-Yarbro, A., Halfmann, P. J., Segaloff, H. E., Kocharian, A., Florek, K. R., Westergaard, R., Bateman, A., Jeppson, G. E., Kawaoka, Y., O’Connor, D. H., Friedrich, T. C., & Grande, K. M. (2022). Shedding of infectious SARS-CoV-2
Reference: Tareq, A. M., Bin Emran, T., Dhama, K., Dhawan, M., & Tallei, T. E. (2021). Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Human Vaccines & Immunotherapeutics, 17(11), 4126–4127. https://doi.org/10.1080/21645515.2021.1963601 Summary: The article examines the impact of the SARS-CoV-2 delta variant
Reference: Benn, C. S., & Aaby, P. (2021). Should COVID-19 be a vaccine disease or a childhood disease? The BMJ, 374, n1687. https://doi.org/10.1136/bmj.n1687 Summary: The article discusses the implications of COVID-19 vaccination for children, highlighting concerns over the safety and necessity of such measures. It critiques the small sample size of the Pfizer phase 3
Reference: Rutenberg, D., & Zhang, Y. (2021). The clot thickens: Does the Johnson & Johnson COVID-19 vaccine increase the risk of thrombus in a hypercoagulable state? Chest, 2195. https://doi.org/10.1016/j.chest.2021.07.1937 Summary: Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to information on the novel coronavirus. The resource centre allows unrestricted sharing